MIMEDX GROUP INC (MDXG) Stock Fundamental Analysis
USA - NASDAQ:MDXG - US6024961012 - Common Stock
7.485 USD
+0 (+0.07%)
We assign a fundamental rating of 6 out of 10 to MDXG. MDXG was compared to 531 industry peers in the Biotechnology industry. MDXG has an excellent financial health rating, but there are some minor concerns on its profitability. MDXG is valued quite cheap, while showing a decent growth score. This is a good combination! These ratings would make MDXG suitable for value investing!
1. Profitability
1.1 Basic Checks
MDXG had positive earnings in the past year.
MDXG had a positive operating cash flow in the past year.
In multiple years MDXG reported negative net income over the last 5 years.
In multiple years MDXG reported negative operating cash flow during the last 5 years.
1.2 Ratios
MDXG's Return On Assets of 12.80% is amongst the best of the industry. MDXG outperforms 94.35% of its industry peers.
With an excellent Return On Equity value of 17.09%, MDXG belongs to the best of the industry, outperforming 94.92% of the companies in the same industry.
MDXG has a Return On Invested Capital of 15.15%. This is amongst the best in the industry. MDXG outperforms 95.86% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 12.8% | ||
| ROE | 17.09% | ||
| ROIC | 15.15% |
ROA(3y)4.7%
ROA(5y)-7.18%
ROE(3y)1.74%
ROE(5y)-20.73%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
MDXG has a better Profit Margin (10.38%) than 92.09% of its industry peers.
MDXG's Operating Margin of 13.73% is amongst the best of the industry. MDXG outperforms 93.03% of its industry peers.
In the last couple of years the Operating Margin of MDXG has remained more or less at the same level.
MDXG's Gross Margin of 81.99% is amongst the best of the industry. MDXG outperforms 85.50% of its industry peers.
In the last couple of years the Gross Margin of MDXG has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 13.73% | ||
| PM (TTM) | 10.38% | ||
| GM | 81.99% |
OM growth 3YN/A
OM growth 5Y-1.06%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.19%
GM growth 5Y-0.67%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), MDXG is creating some value.
MDXG has more shares outstanding than it did 1 year ago.
The number of shares outstanding for MDXG has been increased compared to 5 years ago.
Compared to 1 year ago, MDXG has an improved debt to assets ratio.
2.2 Solvency
An Altman-Z score of 10.57 indicates that MDXG is not in any danger for bankruptcy at the moment.
MDXG's Altman-Z score of 10.57 is amongst the best of the industry. MDXG outperforms 83.99% of its industry peers.
The Debt to FCF ratio of MDXG is 0.27, which is an excellent value as it means it would take MDXG, only 0.27 years of fcf income to pay off all of its debts.
MDXG's Debt to FCF ratio of 0.27 is amongst the best of the industry. MDXG outperforms 95.48% of its industry peers.
MDXG has a Debt/Equity ratio of 0.07. This is a healthy value indicating a solid balance between debt and equity.
MDXG has a worse Debt to Equity ratio (0.07) than 62.52% of its industry peers.
Even though the debt/equity ratio score it not favorable for MDXG, it has very limited outstanding debt, so we won't put too much weight on the DE evaluation.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.07 | ||
| Debt/FCF | 0.27 | ||
| Altman-Z | 10.57 |
ROIC/WACC1.75
WACC8.68%
2.3 Liquidity
A Current Ratio of 4.41 indicates that MDXG has no problem at all paying its short term obligations.
With a Current ratio value of 4.41, MDXG perfoms like the industry average, outperforming 50.09% of the companies in the same industry.
MDXG has a Quick Ratio of 3.95. This indicates that MDXG is financially healthy and has no problem in meeting its short term obligations.
MDXG has a Quick ratio of 3.95. This is comparable to the rest of the industry: MDXG outperforms 48.02% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.41 | ||
| Quick Ratio | 3.95 |
3. Growth
3.1 Past
The earnings per share for MDXG have decreased strongly by -35.71% in the last year.
Looking at the last year, MDXG shows a quite strong growth in Revenue. The Revenue has grown by 14.77% in the last year.
MDXG shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 3.11% yearly.
EPS 1Y (TTM)-35.71%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%200%
Revenue 1Y (TTM)14.77%
Revenue growth 3Y10.5%
Revenue growth 5Y3.11%
Sales Q2Q%35.3%
3.2 Future
Based on estimates for the next years, MDXG will show a quite strong growth in Earnings Per Share. The EPS will grow by 17.40% on average per year.
The Revenue is expected to grow by 12.54% on average over the next years. This is quite good.
EPS Next Y49.48%
EPS Next 2Y8.55%
EPS Next 3Y17.4%
EPS Next 5YN/A
Revenue Next Year17.88%
Revenue Next 2Y9.84%
Revenue Next 3Y10.43%
Revenue Next 5Y12.54%
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
MDXG is valuated rather expensively with a Price/Earnings ratio of 20.79.
94.35% of the companies in the same industry are more expensive than MDXG, based on the Price/Earnings ratio.
Compared to an average S&P500 Price/Earnings ratio of 26.34, MDXG is valued a bit cheaper.
MDXG is valuated rather expensively with a Price/Forward Earnings ratio of 21.91.
Based on the Price/Forward Earnings ratio, MDXG is valued cheaply inside the industry as 92.66% of the companies are valued more expensively.
MDXG is valuated rather cheaply when we compare the Price/Forward Earnings ratio to 34.43, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 20.79 | ||
| Fwd PE | 21.91 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, MDXG is valued cheaply inside the industry as 94.73% of the companies are valued more expensively.
Based on the Price/Free Cash Flow ratio, MDXG is valued cheaply inside the industry as 96.05% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 16.58 | ||
| EV/EBITDA | 14.32 |
4.3 Compensation for Growth
MDXG's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
MDXG has a very decent profitability rating, which may justify a higher PE ratio.
A more expensive valuation may be justified as MDXG's earnings are expected to grow with 17.40% in the coming years.
PEG (NY)0.42
PEG (5Y)N/A
EPS Next 2Y8.55%
EPS Next 3Y17.4%
5. Dividend
5.1 Amount
No dividends for MDXG!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NASDAQ:MDXG (11/13/2025, 10:56:06 AM)
7.485
+0 (+0.07%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners71.57%
Inst Owner Change-1.19%
Ins Owners1.83%
Ins Owner Change0.28%
Market Cap1.11B
Revenue(TTM)393.44M
Net Income(TTM)40.83M
Analysts81.82
Price Target12.44 (66.2%)
Short Float %3.31%
Short Ratio8.67
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)95.82%
Min EPS beat(2)81.55%
Max EPS beat(2)110.08%
EPS beat(4)3
Avg EPS beat(4)41.67%
Min EPS beat(4)-31.92%
Max EPS beat(4)110.08%
EPS beat(8)7
Avg EPS beat(8)78.91%
EPS beat(12)11
Avg EPS beat(12)70.05%
EPS beat(16)12
Avg EPS beat(16)53.63%
Revenue beat(2)2
Avg Revenue beat(2)12.56%
Min Revenue beat(2)6.68%
Max Revenue beat(2)18.43%
Revenue beat(4)4
Avg Revenue beat(4)6.82%
Min Revenue beat(4)0.32%
Max Revenue beat(4)18.43%
Revenue beat(8)6
Avg Revenue beat(8)3.48%
Revenue beat(12)9
Avg Revenue beat(12)3.71%
Revenue beat(16)12
Avg Revenue beat(16)3.45%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)21.15%
EPS NQ rev (3m)31.25%
EPS NY rev (1m)30.77%
EPS NY rev (3m)68.32%
Revenue NQ rev (1m)1.39%
Revenue NQ rev (3m)2.86%
Revenue NY rev (1m)5.61%
Revenue NY rev (3m)8.63%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 20.79 | ||
| Fwd PE | 21.91 | ||
| P/S | 2.81 | ||
| P/FCF | 16.58 | ||
| P/OCF | 16.33 | ||
| P/B | 4.63 | ||
| P/tB | 5.32 | ||
| EV/EBITDA | 14.32 |
EPS(TTM)0.36
EY4.81%
EPS(NY)0.34
Fwd EY4.57%
FCF(TTM)0.45
FCFY6.03%
OCF(TTM)0.46
OCFY6.12%
SpS2.66
BVpS1.61
TBVpS1.41
PEG (NY)0.42
PEG (5Y)N/A
Graham Number3.62
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 12.8% | ||
| ROE | 17.09% | ||
| ROCE | 20.67% | ||
| ROIC | 15.15% | ||
| ROICexc | 33.2% | ||
| ROICexgc | 44.66% | ||
| OM | 13.73% | ||
| PM (TTM) | 10.38% | ||
| GM | 81.99% | ||
| FCFM | 16.98% |
ROA(3y)4.7%
ROA(5y)-7.18%
ROE(3y)1.74%
ROE(5y)-20.73%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5Y-47.46%
ROICexc growth 3YN/A
ROICexc growth 5Y-21.46%
OM growth 3YN/A
OM growth 5Y-1.06%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.19%
GM growth 5Y-0.67%
F-Score6
Asset Turnover1.23
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.07 | ||
| Debt/FCF | 0.27 | ||
| Debt/EBITDA | 0.25 | ||
| Cap/Depr | 6.96% | ||
| Cap/Sales | 0.26% | ||
| Interest Coverage | 36.69 | ||
| Cash Conversion | 98.8% | ||
| Profit Quality | 163.64% | ||
| Current Ratio | 4.41 | ||
| Quick Ratio | 3.95 | ||
| Altman-Z | 10.57 |
F-Score6
WACC8.68%
ROIC/WACC1.75
Cap/Depr(3y)52.31%
Cap/Depr(5y)58.09%
Cap/Sales(3y)0.72%
Cap/Sales(5y)1.07%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-35.71%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%200%
EPS Next Y49.48%
EPS Next 2Y8.55%
EPS Next 3Y17.4%
EPS Next 5YN/A
Revenue 1Y (TTM)14.77%
Revenue growth 3Y10.5%
Revenue growth 5Y3.11%
Sales Q2Q%35.3%
Revenue Next Year17.88%
Revenue Next 2Y9.84%
Revenue Next 3Y10.43%
Revenue Next 5Y12.54%
EBIT growth 1Y-14.78%
EBIT growth 3YN/A
EBIT growth 5Y2.02%
EBIT Next Year35.54%
EBIT Next 3Y15.54%
EBIT Next 5YN/A
FCF growth 1Y787.24%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y522.28%
OCF growth 3YN/A
OCF growth 5YN/A
MIMEDX GROUP INC / MDXG FAQ
Can you provide the ChartMill fundamental rating for MIMEDX GROUP INC?
ChartMill assigns a fundamental rating of 6 / 10 to MDXG.
What is the valuation status of MIMEDX GROUP INC (MDXG) stock?
ChartMill assigns a valuation rating of 7 / 10 to MIMEDX GROUP INC (MDXG). This can be considered as Undervalued.
What is the profitability of MDXG stock?
MIMEDX GROUP INC (MDXG) has a profitability rating of 6 / 10.
What is the valuation of MIMEDX GROUP INC based on its PE and PB ratios?
The Price/Earnings (PE) ratio for MIMEDX GROUP INC (MDXG) is 20.79 and the Price/Book (PB) ratio is 4.63.
What is the financial health of MIMEDX GROUP INC (MDXG) stock?
The financial health rating of MIMEDX GROUP INC (MDXG) is 7 / 10.